Evidence map›Paper›PMID 35733812›Full record

ArticleFrontiers in pediatrics2022

Myeloid-Derived Suppressor Cells and Clinical Outcomes in Children With COVID-19.

Katherine Bline, Angel Andrews, Melissa Moore-Clingenpeel, Sara Mertz, Fang Ye, Victoria Best, Rouba Sayegh, Cristina Tomatis-Souverbielle, Ana M Quintero, Zachary Maynard and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Katherine BlineCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Angel AndrewsCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Melissa Moore-ClingenpeelDivision of Critical Care Medicine, Nationwide Children's Hospital, Columbus, OH, United States.
Sara MertzCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Fang YeCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Victoria BestAbigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.
Rouba SayeghDivision of Infectious Disease, Nationwide Children's Hospital, Columbus, OH, United States.
Cristina Tomatis-SouverbielleCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Ana M QuinteroDivision of Infectious Disease, Nationwide Children's Hospital, Columbus, OH, United States.
Zachary MaynardAbigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.
Rebecca GlowinskiCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Asuncion MejiasCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Octavio RamiloCenter for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, United States.
Nationwide Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although children with COVID-19 account for fewer hospitalizations than adults, many develop severe disease requiring intensive care treatment. Critical illness due to COVID-19 has been associated with lymphopenia and functional immune suppression. Myeloid-derived suppressor cells (MDSCs) potently suppress T cells and are significantly increased in adults with severe COVID-19. The role of MDSCs in the immune response of children with COVID-19 is unknown. Aims: We hypothesized that children with severe COVID-19 will have expansion of MDSC populations compared to those with milder disease, and that higher proportions of MDSCs will correlate with clinical outcomes. Methods: We conducted a prospective, observational study on a convenience sample of children hospitalized with PCR-confirmed COVID-19 and pre-pandemic, uninfected healthy controls (HC). Blood samples were obtained within 48 h of admission and analyzed for MDSCs, T cells, and natural killer (NK) cells by flow cytometry. Demographic information and clinical outcomes were obtained from the electronic medical record and a dedicated survey built for this study. Results: Fifty children admitted to the hospital were enrolled; 28 diagnosed with symptomatic COVID-19 (10 requiring ICU admission) and 22 detected by universal screening (6 requiring ICU admission). We found that children with severe COVID-19 had a significantly higher percentage of MDSCs than those admitted to the ward and uninfected healthy controls. Increased percentages of MDSCs in peripheral blood mononuclear cells (PBMC) were associated with CD4+ T cell lymphopenia. MDSC expansion was associated with longer hospitalizations and need for respiratory support in children admitted with acute COVID-19. Conclusion: These findings suggest that MDSCs are part of the dysregulated immune responses observed in children with severe COVID-19 and may play a role in disease pathogenesis. Future mechanistic studies are required to further understand the function of MDSCs in the setting of SARS-CoV-2 infection in children.

Indexed as

COVID-19immune functionmyeloid-derived suppressor cell (MDSC)pediatricrespiratory diseaseT cell

Identifiers

PMID35733812
PMCPMC9207271
OpenAlexW4281692961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.